Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
Wed, 19/09/2018 - 12:15
0 min
Español
IMG_0229.jpg
Download related document
Select rating
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 1/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 2/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 3/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 4/5
Give ROVI has commenced the marketing of its enoxaparin biosimilar in Spain 5/5
No votes yet
Related
ROVI completes its new Escúzar plant by including a sodium heparin production...
The new facility has meant an investment of 11 million euros This new line, which has now been authorised to commence commercial...
3 min
20/06/2024
First three months 2024 results press release
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
ROVI announces agreement to manufacture pre-filled syringes
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024
See More
Email
Facebook
Twitter
LinkedIn
IMG_0229.jpg